- C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing
- The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others
- The financing was executed as a convertible note with two tranches of $50m, called by the company with additional participation from The Mark Foundation for Cancer Research, Silver Lake
- The company intends to use the funds to accelerate clinical development and commercialization of its C2-Intelligence Platform and to deepen its partnerships with pharmaceutical companies
- C2i provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease
- With the platform, physicians can spot trace amounts of persistent or recurrent cancer much earlier, at far lower levels, to inform treatment decisions
